Ovid Therapeutics (OVID) Long-Term Investments (2021 - 2026)

Ovid Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $42.0 million for Q1 2026.

• Quarterly Long-Term Investments rose 100.69% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (up 100.69% YoY) and the FY2025 annual result came in at $20.8 million, changed N/A from the prior year.
• Long-Term Investments was $42.0 million for Q1 2026 at Ovid Therapeutics, up from $20.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $42.0 million in Q1 2026 and bottomed at $2.2 million in Q2 2022.
• A 5-year average of $16.4 million and a median of $19.2 million in 2023 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments jumped 639.07% — and 2025, when it decreased 5.06%.
• Ovid Therapeutics' Long-Term Investments stood at $5.6 million in 2022, then soared by 213.49% to $17.6 million in 2023, then climbed by 19.85% to $21.1 million in 2024, then slipped by 1.48% to $20.8 million in 2025, then jumped by 101.62% to $42.0 million in 2026.
• Business Quant data shows OVID's Long-Term Investments at $42.0 million in Q1 2026, $20.8 million in Q4 2025, and $20.9 million in Q3 2025.